Benelux countries approve Iluvien for noninfectious posterior uveitis

Iluvien has been approved by the governmental agencies overseeing medical products in Belgium, the Netherlands and Luxemburg, Alimera Sciences announced in a press release.

The marketing authorization allows Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg), a sustained-release intravitreal implant that uses continuous microdosing technology, to be used to reduce the recurrence of noninfectious posterior uveitis affecting the posterior segment of the eye.

“We are pleased to now have the approvals for this new indication for Iluvien across Benelux so that our partner, Horus Pharmaceuticals, can now pursue reimbursement in each of these markets for both diabetic macular edema and posterior segment noninfectious uveitis,” Rick Eiswirth, president and CEO of Alimera, said in the release. “Following a strong launch in France for diabetic macular edema, we are excited to see what Horus can do with Iluvien in these countries, providing us with additional markets in Europe where we believe Iluvien can help physicians control the recurrence of disease in patients who have either of these conditions.”

Iluvien has been approved by the governmental agencies overseeing medical products in Belgium, the Netherlands and Luxemburg, Alimera Sciences announced in a press release.

The marketing authorization allows Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg), a sustained-release intravitreal implant that uses continuous microdosing technology, to be used to reduce the recurrence of noninfectious posterior uveitis affecting the posterior segment of the eye.

“We are pleased to now have the approvals for this new indication for Iluvien across Benelux so that our partner, Horus Pharmaceuticals, can now pursue reimbursement in each of these markets for both diabetic macular edema and posterior segment noninfectious uveitis,” Rick Eiswirth, president and CEO of Alimera, said in the release. “Following a strong launch in France for diabetic macular edema, we are excited to see what Horus can do with Iluvien in these countries, providing us with additional markets in Europe where we believe Iluvien can help physicians control the recurrence of disease in patients who have either of these conditions.”